Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery platform. RBT’s patented TargoSphere® technology enables carrying a broad range of active agents selectively into the center of the immune response - i.e., directly into antigen-presenting cells.
RBT currently applies its TargoSphere® technology successfully in various models of infectious diseases caused by viruses like HCV/ Hepatitis C and HIV/ AIDS and by bacteria like in Tuberculosis, Legionellosis, and MRSA. Yet, any disorder that goes along with either overshooting or insufficient immunity caused by antigen-presenting cells - like chronic inflammations, cancers, allergies, and autoimmune diseases - may be addressed by RBT’s TargoSphere® technology.
RBT’s enabling technology offers an innovative approach to support the development of novel drugs, to render existing drugs more effective, or to provide a path towards extending the intellectual property position of already approved treatments.
RBT already partners a growing number of projects with industry and academia. We gladly welcome your suggestions for further co-developments and collaborations.
Latest News / Meet RBT
Rodos BioTarget GmbH receives funding for developing antibacterial TargoSphere® formulation